Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low Dose Maintenance Fabrazyme in Fabry Disease
NCT00196716Phase 2Completed
- Sponsor
- Sanofi
- Start
- Jun 2003
- Primary completion
- Apr 2006
- Modality
- Replacement Enzymes
- Countries
- 4
01
Overview
Phase 2, open-label, single-arm trial of agalsidase beta in Fabry disease (FD), sponsored by Sanofi. Primary endpoint: Globotriaosylceramide (GL-3) Clearance in Kidney Interstitial Capillary Endothelium at 96 weeks. Started Jun 2003; status: completed.
02
Drugs
agalsidase beta
03
Conditions
Fabry disease (FD)
Beyond the preview
Go deeper on NCT00196716.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00196716.